Evidence map›Paper›PMID 38213539›Full record

ReviewExploration of targeted anti-tumor therapy2023

Facing the conundrum: which first-line therapy should be used for patients with metastatic triple-negative breast cancer carrying germline

Sabah Alaklabi, Arya Mariam Roy, Lubna N Chaudhary, Shipra Gandhi

Open access · diamondAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Exploration of targeted anti-tumor therapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Sabah AlaklabiDepartment of Medical Oncology, Cancer Center of Excellence, King Faisal Specialist Hospital and Research Center, Riyadh 11211, Saudi Arabia.ORCID https://orcid.org/0000-0001-9925-3216
Arya Mariam RoyDepartment of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14203, USA.ORCID https://orcid.org/0000-0003-2509-312X
Lubna N ChaudharyDivision of Hematology/Oncology, Froedtert and Medical College of Wisconsin, Milwaukee, WI 53226, USA.ORCID https://orcid.org/0000-0003-0616-6135
Shipra GandhiDepartment of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14203, USA.ORCID https://orcid.org/0000-0003-3506-0284
Roswell Park Comprehensive Cancer Center · USFroedtert Hospital · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pembrolizumab combined with chemotherapy has been established as the preferred first-line therapy for treating metastatic triple-negative breast cancer (mTNBC) with programmed cell death ligand-1 (PD-L1)-positive disease since its approval for that indication. However, the optimal sequencing of therapy remains an unanswered question for a subset of mTNBC patients who harbor germline breast cancer gene 1/2 (

Indexed as

Metastatic triple-negative breast cancerPoly (ADP-ribose) polymerase inhibitorprogrammed cell death ligand-1sequencing of therapytargeted therapy

Identifiers

PMID38213539
PMCPMC10776593
OpenAlexW4390298282

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.